老年转移性结直肠癌的循证治疗:来自里程碑式临床试验的启示
综述基于老年特异性随机临床试验证据,支持对老年衰弱转移性结直肠癌患者进行治疗降强度与剂量调整以提高耐受性而不损害疗效;老年综合评估驱动的照护可改善结局,但尚未验证用于指导具体治疗选择或调整。
要点
- 老年特异性随机试验支持对老年衰弱mCRC患者治疗降强度与剂量调整,提高耐受性且不损害疗效。
- 老年综合评估驱动的照护可改善老年mCRC患者结局,但尚未验证用于指导具体治疗选择或调整。
- 应停止从年轻人群试验外推,基于前瞻性老年特异性试验数据定义循证方法。
核心结论
- 近期老年特异性随机临床试验证据支持对老年衰弱mCRC患者进行治疗降强度与剂量调整,以提高耐受性而不损害疗效。
- 老年综合评估驱动的照护可进一步改善老年mCRC患者结局,但其尚未被验证用于指导具体治疗选择或调整。
研究设计与样本
- 本文为肿瘤学大查房系列综述,通过病例展示、诊疗挑战描述、相关文献回顾及作者建议的管理方法总结,将原始报告置于临床背景中。
主要发现
- 结直肠癌是美国癌症相关死亡第二大原因,确诊患者中超过半数年龄大于65岁,且随着人口老龄化,未来确诊的老年人预计进一步增加。
- 指导老年mCRC患者管理的前瞻性数据有限,治疗决策常依据实际年龄、体能状态的粗略评估及从年轻人群试验外推。
临床怎么用
- 作者认为应停止外推,基于前瞻性老年特异性临床试验数据为老年mCRC人群定义循证方法。
- 作者指出老年综合评估可全面客观评估患者功能状态、合并症、潜在毒性风险、对生活质量的影响及照护目标,并协助个体化治疗。
局限性
- 老年综合评估尚未被验证用于指导老年mCRC患者的具体治疗选择或调整。
- 指导老年mCRC患者管理的前瞻性数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States with more than half of the patients diagnosed being older than 65 years, and an expected further increase in older adults (OA) diagnosed with this cancer in the coming years as the population ages. Prospective data guiding the management of older patients with metastatic CRC (mCRC) have been limited and treatment decisions for these patients are often guided by chronologic age, crude evaluation of performance status, and extrapolation from trials conducted in younger individuals. Recent evidence from randomized clinical trials specifically designed for OA supports treatment deintensification and dose modification to increase tolerability without compromising efficacy in older, frailer patients with mCRC. Additional studies support the incorporation of geriatric assessment (GA)-driven care to further improve the outcomes of OA with mCRC. Although the use of GA has not been validated in guiding specific treatment selection or modification for OA with mCRC, it provides a comprehensive and objective evaluation of a patient's functional status, comorbidities, risk of potential toxicities, effect on the quality of life, goals of care, and assists with personalizing therapy. With the increase in the number of OA we care for in our practices, it is time to stop extrapolating and define an evidence-based approach for this population that is based on data from prospective elderly specific clinical trials.
引用
- Ioffe D, Dotan E. Evidence-Based Care of Older Adults With Metastatic Colorectal Cancer: Insights From Landmark Clinical Trials. J Clin Oncol. 2023. PMID: 37856768. doi:10.1200/JCO.23.01337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。